Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPG 10101 + peginterferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
**CPG 10101 + peginterferon alfa-2b** was an investigational co-administration regimen evaluated for chronic hepatitis C virus infection, including patients with genotype 1 infection who had relapsed after prior therapy. CPG 10101, also called Actilon, is a synthetic CpG-containing oligodeoxynucleotide that activates Toll-like receptor 9 and induces innate immune responses and antiviral cytokines. Peginterferon alfa-2b is a pegylated recombinant interferon alfa cytokine that activates the type I interferon receptor and downstream antiviral signaling. The regimen was administered as separate subcutaneous agents rather than as a marketed fixed-dose product. Coley Pharmaceutical Group originated CPG 10101, and Pfizer subsequently acquired Coley and its development portfolio.
- Other names
- Actilon + PEG-IntronActilon + peginterferon alfa-2bCPG 10101 + PEG-IntronCPG 10101 + pegylated interferon alfa-2bCPG10101 + PEG-IntronCPG10101 + pegylated interferon alfa-2bpeginterferon alfa-2b + CPG 10101
02
Targets
TLR9 (Toll-like receptor 9)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on CPG 10101 + peginterferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPG 10101 + peginterferon alfa-2b.